Mohammad Imran Khan

Senior Scientist and Team Leader with over 15 years of international research experience in multi-omics–driven precision medicine. Currently based at King Faisal Specialist Hospital & Research Centre (Jeddah), with adjunct academic appointment at Al Faisal University, Riyadh. Proven track record of leading multidisciplinary research programs, establishing advanced genomics and single cell sequencing facilities, and translating fundamental discoveries into clinically relevant insights. Recognized among the world’s top 2% scientists by citation impact and Fellow of the Royal Society of Biology (FRSB). Author of 100+ peer-reviewed publications, multiple patents, and editor for leading journals including Frontiers in Oncology and Noncoding RNA. Extensive experience in grant acquisition, doctoral supervision, academic leadership, and international collaboration, with strong expertise in cancer metabolism, epitranscriptomics, drug resistance, and therapeutic target discovery.

RNA Biology.

Multi-Omics.

Translational Therapeutics Discovery.

Dr. Khan is currently working as a Senior Scientist & Team Leader at the Research Centre, King Faisal Specialist Hospital and Research Centre (KFSH&RC), Jeddah. Before joining KFSH&RC-Jeddah, Dr. Khan worked as an Associate Professor for more than five years at the Department of Biochemistry, King Abdulaziz University (KAU), Saudi Arabia. At KAU-Jeddah, Dr. Khan mentored many Ph.D. students who are now doing their postdoc training in reputed universities like UCSD, Cleveland Clinic, Northwestern University, and Institute Curie.

Dr. Khan is an elected member of Royal Society of Biology, UK and currently holds an additional appointment as Adjunct Professor, at the College of Medicine, Al Faisal University, Riyadh. Dr. Khan’s lab is one of the most prominent labs around the world, studying RNA modifications. Dr. Khan’s laboratory has made seminal discoveries regarding the regulatory role of mRNA acetylation in global metabolism.